UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
 D.C. 20549 



FORM 8-K
CURRENT REPORT 

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934 


Date of report (date of earliest event reported): July 15, 2004



VIVUS, INC
(EXACT NAME OF REGISTRANT AS SPECIFIED IN
 ITS CHARTER)

COMMISSION FILE NUMBER: 0–23490 



DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
 
94–3136179
(I.R.S. EMPLOYER
IDENTIFICATION NO.)



 



1172 CASTRO STREET
MOUNTAIN VIEW, CA
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES
 
 
94040
(ZIP CODE)



 

(650) 934–5200
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING
 AREA CODE) 

 

N/A
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF
 CHANGED SINCE LAST REPORT) 







Item 5.  Other Events and Regulation FD Disclosure.

        On July 14, 2004, the
Registrant issued a press release announcing that data from a recently completed
Phase 2 clinical trial demonstrated that ALISTA, our topical formulation of
alprostadil for the treatment of female sexual arousal disorder (FSAD),
significantly increased the percentage of satisfying sexual events in
pre-menopausal women with FSAD when compared with placebo. The press release is
attached as exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

Item 7.  Exhibits.

(c)  



Exhibit
Number
 
Description

 
 
 

99.1
 
Press Release dated July 14, 2004. 





2




SIGNATURES



        Pursuant to the requirements of the Securities
 Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
 thereunto duly authorized. 


Date: July 15, 2004



 
VIVUS, INC.  
 

 

 

 

 

/s/ LARRY J. STRAUSS   

Larry J. Strauss 
Vice President and Chief Financial Officer

 
 


 



3




VIVUS, INC.

INDEX TO EXHIBITS
The following exhibits are filed herewith:




Exhibit
 
Description

 
 
 

99.1
 
Press Release dated July 14, 2004.



4